Latest Articles about ACOR

Additional Patent for Acorda's Ampyra - Analyst Blog

Zacks Equity Research — Wed, 22 May 2013 23:25:51 Z

Acorda Therapeutics, Inc. ( ACOR ) recently announced that an additional method of use patent (US patent application no. 8,440,703) related to Ampyra twice-daily dosing of less than 15 mg

Acorda Therapeutics, Inc. (ACOR): Today's Most Compelling Stock Buy

David Moenning — Mon, 13 May 2013 20:15:25 Z

SoTM Bull's Eye Report - Today's Most Compelling Buy Monday, May 13, 2013 At StateoftheMarkets.com , we strive to "own the best and ignore the

Acorda Incurs Loss, Maintains Guidance - Analyst Blog

Zacks Equity Research — Mon, 06 May 2013 23:25:55 Z

Acorda Therapeutics Inc. 's ( ACOR ) first quarter 2013 loss (including share-based compensation charges but excluding other special items) of 3 cents per share compared unfavorably with

Acorda Initiates Study on rHIgM22 - Analyst Blog

Zacks Equity Research — Fri, 26 Apr 2013 02:13:37 Z

Acorda Therapeutics, Inc. ( ACOR ) and Mayo Clinic announced the enrollment of the first patient in a phase I safety study of rHIgM22. rHIgM22, a remyelinating monoclonal antibody, is being

Biotech Alkermes Poised To Swell On Pipeline Wins

Investor's Business Daily — Wed, 17 Apr 2013 01:10:00 Z

Chief Executive Richard Pops likes to make it very clear about the company he leads:Alkermes ( ALKS ) is not your run-of-the mill biotech firm. For one thing, it has a thriving commercial

Market Wrap for Tuesday, April 16: Stock Market Rebounds Strongly From Monday's Sharp Losses

Scott Rubin — Wed, 17 Apr 2013 00:21:00 Z

The stock market rebounded strongly on Tuesday after recording steep losses to begin the week on Monday. A surging euro and better than expected housing data helped spur investor confidence.

Mid-Afternoon Market Update: Explosions Rock Downtown Boston, Authorities Unsure if Explosive Devices

Jake L'Ecuyer — Mon, 15 Apr 2013 23:41:06 Z

Toward the end of trading Monday, the Dow traded down 1.26 percent to 14,677.61 while the NASDAQ dropped 2.14 percent to 3,224.64. The S&P also fell, declining 1.78 percent to 1,560.60.

Mid-Day Market Update: Sprint Surges On Dish Network Offer, AuRico Gold Tumbles

Jake L'Ecuyer — Mon, 15 Apr 2013 21:15:55 Z

Midway through trading Monday, the Dow traded down 0.82 percent to 14,742.61 while the NASDAQ dropped 1.19 percent to 3,255.64. The S&P also fell, declining 1.02 percent to 1,572.60.

Acorda Reports Data on Epilepsy Drug - Analyst Blog

Zacks Equity Research — Wed, 27 Mar 2013 00:27:57 Z

Acorda Therapeutics, Inc. ( ACOR ) recently announced data from a phase I study evaluating its epilepsy candidate, diazepam nasal spray. The company is developing diazepam nasal spray for

Acorda Presents GGF2 Data - Analyst Blog

Zacks Equity Research — Sat, 09 Mar 2013 02:15:01 Z

Acorda Therapeutics, Inc. ( ACOR ) recently announced data from a phase I trial (n=40) evaluating the safety, tolerability and exploratory efficacy of glial growth factor 2 (GGF2) in

Earnings Miss at Acorda - Analyst Blog

Zacks Equity Research — Thu, 14 Feb 2013 22:30:01 Z

Acorda Therapeutics Inc.'s ( ACOR ) fourth quarter earnings (including share-based compensation charges but excluding other special items) of 9 cents per share were way below the Zacks

Zacks Rank #5 Additions for Thursday - Tale of the Tape

Zacks Equity Research — Thu, 14 Feb 2013 18:44:01 Z

Here are 5 stocks added to the Zacks Rank #5 ("strong sell") List today: Acorda Therapeutics Inc. ( ACOR ) Activision Blizzard, Inc. ( ATVI ) American Axle &

Acorda Presents Encouraging Data - Analyst Blog

Zacks Equity Research — Tue, 12 Feb 2013 04:25:01 Z

Acorda Therapeutics, Inc. ( ACOR ) recently announced that data from preclinical studies evaluating glial growth factor 2 (GGF2) showed promising recovery of sensorimotor function in a

Acorda Gets US Army Support - Analyst Blog

Zacks Equity Research — Fri, 25 Jan 2013 23:50:01 Z

Acorda Therapeutics, Inc. ( ACOR ) recently announced that it has been awarded a research contract worth $2.67 million by the US Army Medical Research and Material Command (USAMRMC). The

Zacks Rank #5 Additions for Wednesday - Tale of the Tape

Zacks Equity Research — Wed, 23 Jan 2013 18:44:01 Z

Here are 5 stocks added to the Zacks Rank #5 ("strong sell") List today: Acorda Therapeutics Inc. ( ACOR ) Allied Nevada Gold Corp. ( ANV ) Anworth Mortgage Asset Corp .